American Journal of Psychiatry
Fecha de publicación: 1 June 2020
DOI: https://doi.org/10.1176/appi.ajp.2020.20040418
Autores: Susan E. Maloney, Ph.D., Cynthia E. Rogers, M.D., John N. Constantino, M.D.
Background: The prevalence of antenatal depression and anxiety disorder among pregnant women is estimated at 20% and 15%, respectively. Given serious known consequences of these common psychiatric conditions for mothers and their newborns (particularly depression, which exceeds hemorrhage and hypertensive disorders as a cause of maternal mortality), and the fact that rates of maternal antidepressant use in pregnancy have steadily risen in the United States, the stakes of “getting it right” about associations between such use and major adverse neurodevelopmental outcomes among offspring have never been higher.
